What is ORMP's market cap?

$171.80M, based on the Nov 4 close of $4.13.

What is ORMP's P/E ratio?

1.0× trailing-twelve-month earnings of $174.06M.

Does Oramed Pharmaceuticals pay a dividend?

Yes. The latest regular dividend was $0.25 per share (ex-date Jan 16), an annualised yield of 6.05%.

How much of ORMP is sold short?

1.5M shares, 4.3% of float, as of Oct 15, 2026.

What sector is ORMP in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · ORMPHealthcarePharmaceuticals

Oramed Pharmaceuticals Inc. (ORMP)

$4.13+3.25%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$4.09▲ 73.31% in range

Nov 3, 2025Low $2.19 · High $5.34Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Oramed Pharmaceuticals closed at $4.13 on Nov 4, up 3.25%, 22.7% below its 52-week closing high. Volume of 120.1K shares was 0.98× its 20-day average (close to normal).

Split-adjusted performance: -5.7% over one month, +5.4% over six months, +75.0% over one year.

Short interest was 1.5M shares at the Oct 15 settlement, up 1.2% from the prior report (4.3% of float, 10.4 days to cover).

Market cap$171.8M41.6M shares

Revenue · quarter$0.00—

Diluted EPS$1.84+493.5% YoY

P/E · TTM1.0×

Net margin—

Dividend yield6.05%$0.25 last paid

52-week range2.19 – 5.34−22.7% from high

Volume120.1K0.98× 20-day avg

Volatility · 60d36.4%Annualised

Short % of float4.3%10.4 days to cover

Net cash$50.6MCash $50.6M

Next earnings—Not scheduled

Split-adjusted performance

1W −0.7%1M −5.7%3M −4.0%6M +5.4%YTD +44.9%1Y +75.0%3Y +119.7%5Y −82.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum75

Revenue growth—

Net margin—

Value (low P/E)98

Size46

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short1.5M+1.2% vs prior

Days to cover10.4Settled Oct 15

% of float4.3%

Short vol. 10d58.5%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
ORMPOramed Pharmaceuticals	$4.13	+3.25%	+5.4%	—	—	1.0	$171.8M
PEPGPepGen	$2.45	−0.41%	+32.8%	—	—	—	$169.7M	Compare
SIONSionna Therapeutics	$3.73	+2.19%	−91.4%	—	—	—	$168.6M	Compare
INOInovio Pharmaceuticals	$1.62	−2.41%	+30.6%	—	—	—	$167.5M	Compare
ZNTLZentalis Pharmaceuticals	$1.76	−1.12%	−57.9%	—	—	—	$166.6M	Compare
WHWKWhitehawk Therapeutics	$3.17	+2.26%	−23.6%	—	—	—	$180.7M	Compare
ANTXAN2 Therapeutics	$4.25	+1.67%	−8.6%	—	—	—	$160.4M	Compare
BBOTBridgeBio Oncology Therapeutics	$2.30	−0.86%	−72.4%	—	—	—	$184.4M	Compare
ALXOALX Oncology Holdings	$1.36	+5.43%	−34.9%	—	—	—	$188.1M	Compare

News about Oramed Pharmaceuticals

All news →

Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® IndexesBenzinga · Jun 17, 2026▲ Positive Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical CompanyGlobeNewswire Inc. · Mar 13, 2026▲ Positive

Quick answers

What does Oramed Pharmaceuticals do?: Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins.
What is ORMP's market cap?: $171.80M, based on the Nov 4 close of $4.13.
What is ORMP's P/E ratio?: 1.0× trailing-twelve-month earnings of $174.06M.
Does Oramed Pharmaceuticals pay a dividend?: Yes. The latest regular dividend was $0.25 per share (ex-date Jan 16), an annualised yield of 6.05%.
How much of ORMP is sold short?: 1.5M shares, 4.3% of float, as of Oct 15, 2026.
What sector is ORMP in?: Healthcare, in the Pharmaceuticals industry.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.

HQ: New York, NY13 employeesListed Apr 19, 2004oramed.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology